

Correspondence on “EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs” by Bijlsma. Active involvement of the treating rheumatologists increases acceptance of COVID-19 vaccines.

Serena Bugatti^{1,2}, Silvia Balduzzi¹, Ludovico De Stefano^{1,2}, Antonio Manzo^{1,2}, Blerina Xoxi¹, Laura Bogliolo¹, Sara Monti^{1,2}, Paolo Delvino^{1,2}, Carlomaurizio Montecucco^{1,2}

¹Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

²Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Supplementary Material

Supplementary Table S1. Characteristics of the study population and acceptance of COVID-19 vaccination

	Patients n=224
Age, mean (SD), years	56.1 (14.3)
Female gender, n. (%)	156 (69.6%)
Current smokers, n. (%)	31 (13.8)
BMI, mean (SD)	25.8 (5.5)
Obesity, n. (%)	32 (14.3)
Hypertension, n. (%)	78 (34.8)
Diabetes, n. (%)	15 (6.7)
Rheumatic diagnosis, n. (%)	
Rheumatoid arthritis	119 (53.1)
Psoriatic arthritis	46 (20.5)
Spondyloarthritis	43 (19.2)
Vasculitis	16 (7.1)
Disease duration, median (IQR), years	11 (7-17)
Use of oral PDN/equivalents, n. (%)	91 (40.6)
PDN dose, mean (SD), mg/day	4.7 (3.6)
Use of csDMARDs, n. (%)	119 (53.1)
methotrexate	94 (42)
sulphasalazyme	17 (7.6)
leflunomide	7 (3.1)
others	1 (0.4)
Type of b/tsDMARD, n. (%)	
TNF inhibitor	97 (43.3)
IL6-R inhibitor	26 (11.6)
IL17 or IL23 inhibitor	27 (12.1)
CTLA4-Ig	38 (17)
Anti-CD20	10 (4.5)
JAK inhibitor	17 (7.5)
PDE4 inhibitor	9 (4)
Influenza vaccination, n. (%)	148 (66.1)
Acceptance of COVID-19 vaccination with Pfizer/BioNTech	
already vaccinated	23 (10.3)
recent COVID19 willing to be vaccinated	8 (3.5)
hesitants accepting upon rheumatologists' advice	35 (15.6)
immediately endorsing vaccination proposal	135 (60.3)
total number accepting vaccination	201 (89.7%)
Preferences on COVID-19 vaccine	
any	154 (68.8)
uncertain but potentially accepting any upon rheumatologists' advice	11 (4.9)
total number accepting any vaccine	165 (73.7)

BMI = body mass index; PDN = prednisone; DMARD = disease modifying anti-rheumatic drug; cs = conventional synthetic; b/ts = biological/targeted synthetic; TNF = tumor necrosis factor; IL = interleukin; CTLA4 = cytotoxic T-lymphocyte antigen 4; JAK = janus kinase; PDE4 = phosphodiesterase 4.